Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of BI 1181181 in Healthy Volunteers
NCT02254161Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2014
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BI 1181181 in Alzheimer's disease (AD) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Frequency of subjects with drug-related adverse events. Started Nov 2014; status: terminated.
02
Drugs
BI 1181181
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02254161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02254161.